Illustration, AI-generated from the story text. Tap a panel to read the story through it.

Alphabet's drug discovery spinout is negotiating the round, Bloomberg reports, and terms could change.

That is the top of the range Bloomberg described in October and far more money than May's $2.1 billion, led by Thrive Capital. How much of it is new capital and how much buys out existing holders is not reported.

Isomorphic has no approved drug, so the price rests on what its models might do in trials.
Isomorphic Labs is in talks for about $5 billion at about $50 billion, six months after raising $2.1 billion
Alphabet's drug discovery spinout is negotiating the round, Bloomberg reports, and terms could change. That is the top of the range Bloomberg described in October and far more money than May's $2.1 billion, led by Thrive Capital. How much of it is new capital and how much buys out existing holders is not reported. Isomorphic has no approved drug, so the price rests on what its models might do in trials. SourcesBB
Sources
- BIsomorphic Labs in talks for about $5 billion in funding (Bloomberg)bloomberg.com
- BIsomorphic Labs in talks for about $5 billion (Bloomberg via Yahoo Finance UK)uk.finance.yahoo.com
This story ran in the Morning Brief of November 5th 2026.